论文部分内容阅读
α1抗胰蛋白酶(α1-AT)是一种肝脏分泌的糖蛋白,它可以抑制多种蛋白水解酶的活性。血清α1-AT缺乏是一种常染色体隐性遗传性疾病,与肺气肿和肝硬化的发病有关。本文对92例肝疾病(包括肝硬化、原发性肝癌、慢性活动性肝炎)患者进行血清蛋白酶的抑制能力(STIC)测定,以间接反映出血清α1-AT活性水平,并与一组30例健康个体进行对照观察。结果表明:肝硬化患者STIC(g/L)为1.1063±0.145;原发性肝癌为1.079±0.132,慢性活动性肝炎为1.154±0.145,健康对照组则为1.123±0.126。
α1 antitrypsin (α1-AT) is a hepatic secreted glycoprotein that inhibits the activity of various proteolytic enzymes. Serum α1-AT deficiency is an autosomal recessive inherited disease associated with the development of emphysema and cirrhosis. In this paper, 92 cases of liver disease (including cirrhosis, primary liver cancer, chronic active hepatitis) serum protease inhibition (STIC) determination to indirectly reflect the level of serum α1-AT activity, and with a group of 30 patients Healthy individuals were observed. The results showed that the STIC (g / L) in patients with cirrhosis was 1.1063 ± 0.145, that of primary liver cancer was 1.079 ± 0.132, that of chronic active hepatitis was 1.154 ± 0.145, and that of healthy controls was 1.123 ± 0.126.